PHG - Philips' Collaboration Live gets FDA nod for diagnostic use on additional platforms

Royal Philips (NYSE:PHG) said its Collaboration Live received expansion of its U.S. Food & Drug Administration 510(k) market clearance for remote diagnostic use on additional mobile platforms. Available on Philips Ultrasound Systems EPIQ and Affiniti, Collaboration Live allows clinicians to collaborate in real-time with colleagues to complete image acquisition and diagnosis, regardless of location. The company said clinicians now have the ability to consult or diagnose from their mobile device, check the strength of their bandwidth before making a call, and check their remote screen calibration to ensure image quality is appropriate for diagnosis. PHG -0.58% premarket to $30.84

For further details see:

Philips' Collaboration Live gets FDA nod for diagnostic use on additional platforms